CN¥95.66
12.67%
Hong Kong, Nov 04, 03:00 pm HKT. Closed.
Why the stock moved Why the stock moved Beta
ISIN
CNE1000048G6
Symbol
9995

RemeGen Stock price

CN¥95.66
-21.68 18.48% 1M
-33.65 26.02% 6M
+17.87 22.97% YTD
-1.08 1.12% 1Y
+28.03 41.45% 3Y
+54.82 134.23% 5Y
+54.82 134.23% 10Y
+54.82 134.23% 20Y
Hong Kong, Closing price Wed, Nov 04 2026
+10.76 12.67%
ISIN
CNE1000048G6
Symbol
9995
Industry

AI Insights on RemeGen Insights AI Insights on RemeGen

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is RemeGen a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,100 stocks worldwide.

Key metrics

Basic
Market capitalization
CN¥44.6b
Enterprise Value
CN¥39.7b
Net debt
-
Cash
-
Shares outstanding
-
Valuation
P/E
7.3
P/S | estimate
5.4 | 6.0
EV/Sales | estimate
4.8 | 5.3
EV/FCF | ex SBC
10.5 | -
P/B
5.4
Financial Health
Equity Ratio
49.8%
Return on Equity
19.7%
ROCE
59.8%
ROIC
129.6%
Debt/Equity
-
Financials
Revenue | estimate
CN¥8.3b | CN¥7.5b
EBITDA
-
EBIT
CN¥5.1b
Net Income
CN¥6.5b
Free Cash Flow | ex SBC
CN¥3.8b | -
Growth
Revenue | estimate
272.3% | 129.2%
EBITDA
-
EBIT
696.5%
Net Income
789.9%
Free Cash Flow
1,273.6%
Margin
Gross
93.1%
EBITDA
-
EBIT
61.2%
Net
78.8%
Free Cash Flow | ex SBC
45.7% | -
More
EPS
CN¥11.6
FCF per Share
CN¥6.7
Short interest
-
Employees
3k
Rev per Employee
CN¥1.1m

RemeGen Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a RemeGen forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a RemeGen forecast:

Buy
82%
Hold
18%

RemeGen Events

Past Events
OCT
29
Q3 2026 Earnings Call
6 days ago

Financial data from RemeGen

Sep '26
+/-
%
8,295 8,295
272% 272%
100%
- Direct Costs 571 571
50% 50%
7%
7,724 7,724
318% 318%
93%
- Selling and Administrative Expenses 1,650 1,650
13% 13%
20%
- Research and Development Expense 1,023 1,023
20% 20%
12%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 5,074 5,074
696% 696%
61%
Net Profit 6,534 6,534
790% 790%
79%

In millions CNY.

Don't miss a Thing! We will send you all news about RemeGen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

RemeGen Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Yantai, Shandong and currently employs 2,999 full-time employees. The company went IPO on 2020-11-09. RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The firm focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The firm's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The firm mainly operates its businesses in the domestic and overseas markets.

Head office China
CEO Mr. Fang
Employees 3,048
Website www.remegen.cn

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today